BMY
Bristol-Myers Squibb CompanyNYSEHealthcare$59.60-3.45%OpenMarket Cap: $121.37B
As of 2026-04-06
Valuation
P/E (TTM)
17.21
PEG
0.10
P/B
6.58
P/S
2.52
EV/EBITDA
10.88
DCF Value
$285.12
FCF Yield
10.6%
Div Yield
4.2%
Margins & Returns
Gross Margin
67.6%
Operating Margin
26.3%
Net Margin
14.6%
ROE
39.3%
ROA
14.4%
ROIC
13.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $12.50B | 67.2% | $1.42B | $1.09B | $0.53 | $0.62 |
| FY 2025 | $48.19B | 67.6% | $12.70B | $7.05B | $3.45 | $2.48 |
| Q3 2025 | $12.22B | 71.9% | $3.64B | $2.20B | $1.08 | $0.62 |
| Q2 2025 | $12.27B | 65.8% | $4.12B | $1.31B | $0.64 | $0.62 |
| Q1 2025 | $11.20B | 65.5% | $3.52B | $2.46B | $1.20 | $0.62 |
| Q4 2024 | $12.34B | 60.2% | $2.53B | $72.0M | $0.04 | $0.60 |
| FY 2024 | $48.30B | 56.8% | $9.66B | $-8.95B | $-4.41 | $2.40 |
| Q3 2024 | $11.89B | 55.6% | $2.29B | $1.21B | $0.60 | $0.60 |
| Q2 2024 | $12.20B | 55.7% | $2.58B | $1.68B | $0.83 | $0.60 |
| Q1 2024 | $11.87B | 55.5% | $1.53B | $-11.91B | $-5.89 | $0.60 |
| Q4 2023 | $11.48B | 56.6% | $1.95B | $1.76B | $0.87 | $0.57 |
| FY 2023 | $45.01B | 56.3% | $8.47B | $8.03B | $3.86 | $2.28 |